Syndax-2026-JPM.pdf

1、J.P.Morgan 44th Annual Healthcare ConferenceJanuary 12,2026Forward-looking statements disclosureThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.Words such asmay,will,expect,plan,anticipate and similar expressions(as wel

2、l as other words or expressions referencing future events,progress,timing or circumstances)are intended to identify forward-looking statements.All statements other than statements of historical facts containedin this presentation,including statements regarding future operations,financial results and

3、 the financial condition of Syndax Pharmaceuticals,Inc.(“Syndax”or the“Company”),including financial position,strategy and plans,the progress,timing,clinical development and scope ofclinical trials and the reporting of clinical data for Syndaxs product candidates,the progress of regulatory submissio

4、ns and approvals andsubsequent commercialization and the potential use of Syndaxs product candidates to treat various cancer indications and fibrotic diseases,andSyndaxs expectations for liquidity and future operations,are forward-looking statements.Many factors may cause differences between current

5、expectations and actual results,including unexpected safety or efficacy data observed during preclinical studies or clinical trials,clinical siteactivation rates or clinical trial enrollment rates that are lower than expected;changes in expected or existing competition;the impact ofmacroeconomic con

6、ditions(the Russia-Ukraine war,inflation,among others)on Syndaxs business and that of the third parties on which Syndaxdepends,including delaying or otherwise disrupting Syndaxs clinical trials and preclinical studies,manufacturing and supply chain,or impairingemployee productivity;failure of our co